vs

Side-by-side financial comparison of GREENPOWER MOTOR Co INC. (GP) and Arcus Biosciences, Inc. (RCUS). Click either name above to swap in a different company.

Arcus Biosciences, Inc. is the larger business by last-quarter revenue ($11.0M vs $7.2M, roughly 1.5× GREENPOWER MOTOR Co INC.). GREENPOWER MOTOR Co INC. runs the higher net margin — -65.6% vs -963.6%, a 898.0% gap on every dollar of revenue. On growth, GREENPOWER MOTOR Co INC. posted the faster year-over-year revenue change (-11.5% vs -52.2%).

GreenPower Motor Company Inc. is a Canadian electric bus manufacturer and distributor in North America. The company fabricates multiple zero-emission models, including transit buses, school buses, and double decker buses. GreenPower headquarters are in Vancouver, British Columbia, with a sales office in Rancho Cucamonga, California; an assembly facility in Porterville, California; and a production facility in South Charleston, West Virginia. Its stock is traded on Nasdaq the United States.

Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.

GP vs RCUS — Head-to-Head

Bigger by revenue
RCUS
RCUS
1.5× larger
RCUS
$11.0M
$7.2M
GP
Growing faster (revenue YoY)
GP
GP
+40.7% gap
GP
-11.5%
-52.2%
RCUS
Higher net margin
GP
GP
898.0% more per $
GP
-65.6%
-963.6%
RCUS

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
GP
GP
RCUS
RCUS
Revenue
$7.2M
$11.0M
Net Profit
$-4.7M
$-106.0M
Gross Margin
14.6%
Operating Margin
-1036.4%
Net Margin
-65.6%
-963.6%
Revenue YoY
-11.5%
-52.2%
Net Profit YoY
-2.1%
-12.8%
EPS (diluted)
$-0.17
$-0.88

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GP
GP
RCUS
RCUS
Q4 25
$11.0M
Q3 25
$6.0M
Q2 25
$8.0M
Q1 25
$8.0M
Q4 24
$7.2M
$23.0M
Q3 24
$5.3M
$7.0M
Q2 24
$3.0M
$11.0M
Q1 24
$10.0M
Net Profit
GP
GP
RCUS
RCUS
Q4 25
$-106.0M
Q3 25
$-135.0M
Q2 25
$0
Q1 25
$-112.0M
Q4 24
$-4.7M
$-94.0M
Q3 24
$-4.7M
$-92.0M
Q2 24
$-5.4M
$-93.0M
Q1 24
$-4.0M
Gross Margin
GP
GP
RCUS
RCUS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
14.6%
Q3 24
8.6%
Q2 24
7.4%
Q1 24
Operating Margin
GP
GP
RCUS
RCUS
Q4 25
-1036.4%
Q3 25
-2366.7%
Q2 25
-100.0%
Q1 25
-1525.0%
Q4 24
-447.8%
Q3 24
-1500.0%
Q2 24
-963.6%
Q1 24
-160.0%
Net Margin
GP
GP
RCUS
RCUS
Q4 25
-963.6%
Q3 25
-2250.0%
Q2 25
Q1 25
-1400.0%
Q4 24
-65.6%
-408.7%
Q3 24
-87.9%
-1314.3%
Q2 24
-179.8%
-845.5%
Q1 24
-40.0%
EPS (diluted)
GP
GP
RCUS
RCUS
Q4 25
$-0.88
Q3 25
$-1.27
Q2 25
$0.00
Q1 25
$-1.14
Q4 24
$-0.17
$-1.07
Q3 24
$-0.18
$-1.00
Q2 24
$-0.21
$-1.02
Q1 24
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GP
GP
RCUS
RCUS
Cash + ST InvestmentsLiquidity on hand
$621.1K
$222.0M
Total DebtLower is stronger
$99.0M
Stockholders' EquityBook value
$2.1M
$631.0M
Total Assets
$37.4M
$1.1B
Debt / EquityLower = less leverage
0.16×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GP
GP
RCUS
RCUS
Q4 25
$222.0M
Q3 25
$238.0M
Q2 25
$248.0M
Q1 25
$192.0M
Q4 24
$621.1K
$150.0M
Q3 24
$116.9K
$201.0M
Q2 24
$528.3K
$156.0M
Q1 24
$185.0M
Total Debt
GP
GP
RCUS
RCUS
Q4 25
$99.0M
Q3 25
$98.0M
Q2 25
$97.0M
Q1 25
$48.0M
Q4 24
$48.0M
Q3 24
$47.0M
Q2 24
Q1 24
Stockholders' Equity
GP
GP
RCUS
RCUS
Q4 25
$631.0M
Q3 25
$436.0M
Q2 25
$549.0M
Q1 25
$531.0M
Q4 24
$2.1M
$485.0M
Q3 24
$4.2M
$565.0M
Q2 24
$8.6M
$635.0M
Q1 24
$707.0M
Total Assets
GP
GP
RCUS
RCUS
Q4 25
$1.1B
Q3 25
$974.0M
Q2 25
$1.1B
Q1 25
$1.2B
Q4 24
$37.4M
$1.1B
Q3 24
$39.4M
$1.3B
Q2 24
$43.5M
$1.2B
Q1 24
$1.3B
Debt / Equity
GP
GP
RCUS
RCUS
Q4 25
0.16×
Q3 25
0.22×
Q2 25
0.18×
Q1 25
0.09×
Q4 24
0.10×
Q3 24
0.08×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GP
GP
RCUS
RCUS
Operating Cash FlowLast quarter
$-1.1M
$-120.0M
Free Cash FlowOCF − Capex
$-121.0M
FCF MarginFCF / Revenue
-1100.0%
Capex IntensityCapex / Revenue
9.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GP
GP
RCUS
RCUS
Q4 25
$-120.0M
Q3 25
$-97.0M
Q2 25
$-133.0M
Q1 25
$-132.0M
Q4 24
$-1.1M
$-100.0M
Q3 24
$-1.3M
$26.0M
Q2 24
$-3.2M
$-94.0M
Q1 24
$-2.0M
Free Cash Flow
GP
GP
RCUS
RCUS
Q4 25
$-121.0M
Q3 25
Q2 25
Q1 25
$-133.0M
Q4 24
$-101.0M
Q3 24
$25.0M
Q2 24
Q1 24
$-6.0M
FCF Margin
GP
GP
RCUS
RCUS
Q4 25
-1100.0%
Q3 25
Q2 25
Q1 25
-1662.5%
Q4 24
-439.1%
Q3 24
357.1%
Q2 24
Q1 24
-60.0%
Capex Intensity
GP
GP
RCUS
RCUS
Q4 25
9.1%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
12.5%
Q4 24
4.3%
Q3 24
14.3%
Q2 24
0.0%
Q1 24
40.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GP
GP

Segment breakdown not available.

RCUS
RCUS

Other$5.0M45%
Other Collaboration Revenue$4.0M36%
Access Rights And Option Continuation Periods$2.0M18%

Related Comparisons